Aquilo Capital Management, LLC Argenx Se Transaction History

Aquilo Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$369.35 - $548.43 $4.65 Million - $6.91 Million	-12,600 Reduced 77.23%	3,715 $1.83 Million
Q2 2023 Aug 14, 2023	SELL	$360.14 - $422.58 $2.77 Million - $3.25 Million	-7,685 Reduced 32.02%	16,315 $6.36 Million
Q1 2022 May 16, 2022	BUY	$254.45 - $351.06 $458,010 - $631,908	1,800 Added 8.11%	24,000 $7.57 Million
Q3 2021 Nov 15, 2021	BUY	$295.0 - $350.58 $295,000 - $350,580	1,000 Added 4.72%	22,200 $6.7 Million
Q1 2021 May 17, 2021	BUY	$268.3 - $380.31 $2.28 Million - $3.23 Million	8,500 Added 66.93%	21,200 $5.84 Million
Q4 2020 Feb 16, 2021	BUY	$248.13 - $308.36 $1.29 Million - $1.6 Million	5,200 Added 69.33%	12,700 $3.74 Million
Q3 2020 Nov 16, 2020	SELL	$215.51 - $272.51 $6.1 Million - $7.71 Million	-28,300 Reduced 79.05%	7,500 $1.97 Million
Q2 2020 Aug 14, 2020	BUY	$127.44 - $232.72 $4.56 Million - $8.33 Million	35,800 New	35,800 $8.06 Million
Q1 2019 May 15, 2019	SELL	$98.85 - $134.59 $4.53 Million - $6.17 Million	-45,806 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$63.81 - $109.82 $2.92 Million - $5.03 Million	45,806 New	45,806 $4.4 Million

403

30.8M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $36.3B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Aquilo Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Aquilo Capital Management, LLC with notifications on news.